Link to All Articles

Jan 31 2008, 12:33 PM EST
Abbott Pays $20M for a 10.25% Equity Stake in Ibis Biosciences
Abbott could up its ownership to 18.6% with an additional $20 million before July 31 and acquire the firm entirely for $175 to $210 million before June 30, 2009.Full Story

Jan 31 2008, 12:27 PM EST
Laureate Inks Manufacturing Contract to Help Arius Advance Cancer Program
Company will produce Trop-2 targeting antibody.Full Story

Jan 31 2008, 12:32 PM EST
SAFC Initiates Second Phase of a $600K Research Facility Expansion
Site is scheduled for completion in the first quarter.Full Story

Jan 31 2008, 12:25 PM EST
Eden Biodesign and iQur Enter Vacine Deal
Eden will set up an optimized biomanufacturing process before proceeding with clinical trial cGMP manufacture for Hep. A and B combined vaccine.Full Story

Jan 30 2008, 11:27 AM EST
miRNA Expression Pattern Distinguishes Cancerous and Noncancerous Tissue
Paper published in JAMA showed that miR-21 was associated with poor survival outcome and response to adjuvant chemotherapy.Full Story

Jan 29 2008, 12:04 PM EST
Sepracor Expands Respiratory Disease Franchise through $430M Licensing Agreement with Nycomed
Firm gains two approved products, the API, ciclesonide, and three line-extension programs.Full Story

Jan 29 2008, 12:02 PM EST
Scientists Map Role of Proteins in Neuron Differentiation
Study published in PNAS showed how GEF and GAP proteins control neuritogenesis by modulating signaling.Full Story

Jan 29 2008, 11:59 AM EST
Cryo-Cell and Saneron Sign Neurodegenerative Disorder Deal Using Stem Cell Technology
C'elle menstrual stem cell platform will be used in preclinical models of CNS diseases.Full Story

Jan 28 2008, 11:13 AM EST
Labcyte and Deerac Combine Forces to Enhance Low-Volume Liquid Handling
The merged firm will offer products that cover a greater number of applications and different volume ranges.Full Story

Jan 25 2008, 11:52 AM EST
TransTech Pharma Acquires Three Programs Related to Metabolic Disorders from Novo Nordisk
Approaches target the H3 receptor antagonists, PPARd agonists, and 11ßHSD1 inhibitors.Full Story

GenEngNews.com